DGAP-News

aap: Sales in Q4/2016 at EUR 2.4 million and in FY/2016 at EUR 11.2 million; sales growth in established markets and EBITDA improvement planned for FY/2017

DGAP-News: aap Implantate AG / Key word(s): Preliminary Results/Forecast aap: Sales in Q4/2016 at EUR 2.4 million and in FY/2016 at EUR 11.2 million; sales growth in established markets and EBITDA improvement planned for FY/2017 28.02.2017 / 22:12 The issuer is solely responsible for the content of this announcement. - Challenging FY/2016 with progress in strategic implementation - Transformation into pure player in trauma completed - Forecast for FY/2017: Sales between EUR 10.0 million and EUR 13.0 million and EBITDA between EUR -6.5 million and EUR -4.5 million; dynamic development expected from the second half of the year - Growth drivers of planned sales development are established markets, such as North America, the DACH region, and further European countries - EBITDA improvement shall be achieved by raising gross margin from sales in higher margin markets while at the same time reducing costs

Sales development in 2016

aap Implantate AG ("aap") achieved sales of EUR 2.4 million in the continued operation in the fourth quarter of 2016 (Q4/2015: EUR 2.4 million) according to preliminary figures. As such, the company generated sales of EUR 11.2 million in the continued operation in financial year 2016 as a whole (FY/2015: EUR 12.3 million), which were therefore within the guidance of EUR 11.0 million to EUR 12.1 million as published in December 2016.

Q4/2016 Sales

In EUR million	Q4/2016	Q4/2015	Change on year
Trauma	2.0	2.0	N/C
Other	0.4	0.4	N/C
Sales continued operation	2.4	2.4	N/C